+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07039201

Study of CG-102-12C CAR-T Cell Therapy for Adults With Glypican-3 Positive Advanced Hepatocellular Carcinoma Who Have Had Previous Treatments

Led by Zhejiang University · Updated on 2026-01-22

12

Participants Needed

2

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CG-102-12C, a type of autologous chimeric antigen receptor T-cell therapy, in adults with advanced hepatocellular carcinoma HCC that tests positive for glypican-3 GPC3. This exploratory, single-center study focuses on participants who have previously received systemic treatments that were ineffective or not tolerated. The goal is to assess safety, tolerability, dosing, anti-tumor effects, and how the drug behaves in the body. Participants will receive a single infusion of CG-102-12C in a dose-escalation design across three dose groups, with about 7 to 12 participants per group. The study is open-label and does not include a placebo group. The treatment phase examines different doses to identify the recommended dose and monitor immediate responses and side effects. During the study, participants will be closely monitored for dose-limiting toxicities within 28 days after infusion and treatment-emergent adverse events for up to 24 months. Researchers will assess tumor response, disease control, remission duration, progression-free and overall survival, and pharmacokinetic parameters over follow-up periods that may last up to five years. Participants will undergo lab tests, tumor evaluations by imaging, and other clinical assessments throughout the study period.

CONDITIONS

Brief Title

A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)

Research Team

Q

Qi Zhang, Professor

F

Fan Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here